{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T05:34:52Z","timestamp":1761197692200},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T00:00:00Z","timestamp":1565654400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T00:00:00Z","timestamp":1565654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s10067-019-04737-5","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T10:02:50Z","timestamp":1565690570000},"page":"3511-3519","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Predictors of poor response to urate-lowering therapy in patients with gout and hyperuricemia: a post-hoc analysis of a multicenter randomized trial"],"prefix":"10.1007","volume":"38","author":[{"given":"Zepeng","family":"Mu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenshan","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingfei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongchao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,13]]},"reference":[{"issue":"10055","key":"4737_CR1","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1016\/S0140-6736(16)00346-9","volume":"388","author":"N Dalbeth","year":"2016","unstructured":"Dalbeth N, Merriman TR, Stamp LK (2016) Gout. Lancet 388(10055):2039\u20132052. \nhttps:\/\/doi.org\/10.1016\/S0140-6736(16)00346-9","journal-title":"Lancet"},{"issue":"10","key":"4737_CR2","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Liote F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, Robbins M, Wenger N, Terkeltaub R, American College of R (2012) 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 64(10):1431\u20131446. \nhttps:\/\/doi.org\/10.1002\/acr.21772","journal-title":"Arthritis Care Res"},{"issue":"4","key":"4737_CR3","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3899\/jrheum.170806","volume":"45","author":"MM Elfishawi","year":"2018","unstructured":"Elfishawi MM, Zleik N, Kvrgic Z, Michet CJ Jr, Crowson CS, Matteson EL, Bongartz T (2018) The rising incidence of gout and the increasing burden of comorbidities: a population-based study over 20 years. J Rheumatol 45(4):574\u2013579. \nhttps:\/\/doi.org\/10.3899\/jrheum.170806","journal-title":"J Rheumatol"},{"key":"4737_CR4","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1093\/rheumatology\/key390","volume":"58","author":"K Zobbe","year":"2018","unstructured":"Zobbe K, Prieto-Alhambra D, Cordtz R, Hojgaard P, Hindrup JS, Kristensen LE, Dreyer L (2018) Secular trends in the incidence and prevalence of gout in Denmark from 1995 to 2015: a nationwide register-based study. Rheumatology. 58:836\u2013839. \nhttps:\/\/doi.org\/10.1093\/rheumatology\/key390","journal-title":"Rheumatology."},{"issue":"10","key":"4737_CR5","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1002\/art.30520","volume":"63","author":"Y Zhu","year":"2011","unstructured":"Zhu Y, Pandya BJ, Choi HK (2011) Prevalence of gout and hyperuricemia in the US general population: the national health and nutrition examination survey 2007-2008. Arthritis Rheum 63(10):3136\u20133141. \nhttps:\/\/doi.org\/10.1002\/art.30520","journal-title":"Arthritis Rheum"},{"issue":"21","key":"4737_CR6","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1001\/jama.2016.3517","volume":"315","author":"SY Lim","year":"2016","unstructured":"Lim SY, Lu N, Oza A, Fisher M, Rai SK, Menendez ME, Choi HK (2016) Trends in gout and rheumatoid arthritis hospitalizations in the United States, 1993-2011. Jama 315(21):2345\u20132347. \nhttps:\/\/doi.org\/10.1001\/jama.2016.3517","journal-title":"Jama"},{"issue":"11","key":"4737_CR7","doi-asserted-by":"publisher","first-page":"892","DOI":"10.3760\/cma.j.issn.0578-1426.2016.11.019","volume":"55","author":"Z Xiaofeng","year":"2017","unstructured":"Xiaofeng Z, Yaolong C (2017) 2016 China guidelines for management of gout. Chin J Intern Med 55(11):892\u2013899. \nhttps:\/\/doi.org\/10.3760\/cma.j.issn.0578-1426.2016.11.019","journal-title":"Chin J Intern Med"},{"key":"4737_CR8","doi-asserted-by":"publisher","first-page":"f5648","DOI":"10.1136\/bmj.f5648","volume":"347","author":"E Roddy","year":"2013","unstructured":"Roddy E, Mallen CD, Doherty M (2013) Gout. BMJ 347:f5648. \nhttps:\/\/doi.org\/10.1136\/bmj.f5648","journal-title":"BMJ"},{"issue":"10","key":"4737_CR9","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.3899\/jrheum.151199","volume":"43","author":"R Wood","year":"2016","unstructured":"Wood R, Fermer S, Ramachandran S, Baumgartner S, Morlock R (2016) Patients with gout treated with conventional urate-lowering therapy: association with disease control, health-related quality of life, and work productivity. J Rheumatol 43(10):1897\u20131903. \nhttps:\/\/doi.org\/10.3899\/jrheum.151199","journal-title":"J Rheumatol"},{"issue":"1","key":"4737_CR10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1080\/03007995.2016.1239193","volume":"33","author":"A Shiozawa","year":"2017","unstructured":"Shiozawa A, Buysman EK, Korrer S (2017) Serum uric acid levels and the risk of flares among gout patients in a US managed care setting. Curr Med Res Opin 33(1):117\u2013124. \nhttps:\/\/doi.org\/10.1080\/03007995.2016.1239193","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"4737_CR11","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1517\/14656560902950742","volume":"10","author":"N Schlesinger","year":"2009","unstructured":"Schlesinger N, Dalbeth N, Perez-Ruiz F (2009) Gout\u2013what are the treatment options? Expert Opin Pharmacother 10(8):1319\u20131328. \nhttps:\/\/doi.org\/10.1517\/14656560902950742","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"4737_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J, Coyfish M, Guillo S, Jansen TL, Janssens H, Liote F, Mallen C, Nuki G, Perez-Ruiz F, Pimentao J, Punzi L, Pywell T, So A, Tausche AK, Uhlig T, Zavada J, Zhang W, Tubach F, Bardin T (2017) 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 76(1):29\u201342. \nhttps:\/\/doi.org\/10.1136\/annrheumdis-2016-209707","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"4737_CR13","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/acr.22469","volume":"67","author":"SP Juraschek","year":"2015","unstructured":"Juraschek SP, Kovell LC, Miller ER 3rd, Gelber AC (2015) Gout, urate-lowering therapy, and uric acid levels among adults in the United States. Arthritis Care Res 67(4):588\u2013592. \nhttps:\/\/doi.org\/10.1002\/acr.22469","journal-title":"Arthritis Care Res"},{"issue":"11","key":"4737_CR14","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/art.24209","volume":"59","author":"HR Schumacher Jr","year":"2008","unstructured":"Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N (2008) Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 59(11):1540\u20131548. \nhttps:\/\/doi.org\/10.1002\/art.24209","journal-title":"Arthritis Rheum"},{"issue":"1","key":"4737_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3760\/cma.j.issn.0578-1426.2018.01.005","volume":"57","author":"H Luo","year":"2018","unstructured":"Luo H, Fang WG, Zuo XX, Wu R, Li XX, Chen JW, Zhou JG, Yang J, Song H, Duan XJ, Lin XF, Zeng XW, Zeng H (2018) The clinical characteristics, diagnosis and treatment of patients with gout in China. Zhonghua Nei Ke Za Zhi 57(1):27\u201331. \nhttps:\/\/doi.org\/10.3760\/cma.j.issn.0578-1426.2018.01.005","journal-title":"Zhonghua Nei Ke Za Zhi"},{"issue":"8","key":"4737_CR16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11926-018-0760-2","volume":"20","author":"GG Graham","year":"2018","unstructured":"Graham GG, Stocker SL, Kannangara DRW, Day RO (2018) Predicting response or non-response to urate-lowering therapy in patients with gout. Curr Rheumatol Rep 20(8):47. \nhttps:\/\/doi.org\/10.1007\/s11926-018-0760-2","journal-title":"Curr Rheumatol Rep"},{"issue":"10","key":"4737_CR17","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208237","volume":"74","author":"T Neogi","year":"2015","unstructured":"Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, Brown M, Choi H, Edwards NL, Janssens HJ, Liote F, Naden RP, Nuki G, Ogdie A, Perez-Ruiz F, Saag K, Singh JA, Sundy JS, Tausche AK, Vaquez-Mellado J, Yarows SA, Taylor WJ (2015) 2015 Gout classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 74(10):1789\u20131798. \nhttps:\/\/doi.org\/10.1136\/annrheumdis-2015-208237","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"4737_CR18","first-page":"913","volume":"29","author":"Endocrinology CSo","year":"2013","unstructured":"Endocrinology CSo (2013) Chinese expert consensus on hyperuricemia and gout treatment. Chin J Endocrinol Metab 29(11):913\u2013920","journal-title":"Chin J Endocrinol Metab"},{"key":"4737_CR19","doi-asserted-by":"publisher","first-page":"629","DOI":"10.2147\/CEOR.S139939","volume":"9","author":"R Sheer","year":"2017","unstructured":"Sheer R, Null KD, Szymanski KA, Sudharshan L, Banovic J, Pasquale MK (2017) Predictors of reaching a serum uric acid goal in patients with gout and treated with febuxostat. Clinicoecon Outcomes Res 9:629\u2013639. \nhttps:\/\/doi.org\/10.2147\/CEOR.S139939","journal-title":"Clinicoecon Outcomes Res"},{"issue":"2","key":"4737_CR20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3810\/pgm.2014.03.2741","volume":"126","author":"H Hatoum","year":"2014","unstructured":"Hatoum H, Khanna D, Lin SJ, Akhras KS, Shiozawa A, Khanna P (2014) Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat. Postgrad Med 126(2):65\u201375. \nhttps:\/\/doi.org\/10.3810\/pgm.2014.03.2741","journal-title":"Postgrad Med"},{"issue":"2","key":"4737_CR21","first-page":"110","volume":"21","author":"Y Fei","year":"2017","unstructured":"Fei Y, Cong Y, Wei T, Guifeng S, Linli D, Shaoxian H, Yikai Y, Ting Y (2017) Analysis of factors influencing the therapeutic effect of lowering uric acid in patients with gout. Chin J Rheumatol 21(2):110\u2013113","journal-title":"Chin J Rheumatol"},{"issue":"7","key":"4737_CR22","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1001\/archinte.165.7.742","volume":"165","author":"HK Choi","year":"2005","unstructured":"Choi HK, Atkinson K, Karlson EW, Curhan G (2005) Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med 165(7):742\u2013748. \nhttps:\/\/doi.org\/10.1001\/archinte.165.7.742","journal-title":"Arch Intern Med"},{"issue":"55","key":"4737_CR23","doi-asserted-by":"publisher","first-page":"94893","DOI":"10.18632\/oncotarget.22046","volume":"8","author":"J Zhou","year":"2017","unstructured":"Zhou J, Wang Y, Lian F, Chen D, Qiu Q, Xu H, Liang L, Yang X (2017) Physical exercises and weight loss in obese patients help to improve uric acid. Oncotarget 8(55):94893\u201394899. \nhttps:\/\/doi.org\/10.18632\/oncotarget.22046","journal-title":"Oncotarget"},{"issue":"2","key":"4737_CR24","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.cmet.2007.01.005","volume":"5","author":"KJ Cheung","year":"2007","unstructured":"Cheung KJ, Tzameli I, Pissios P, Rovira I, Gavrilova O, Ohtsubo T, Chen Z, Finkel T, Flier JS, Friedman JM (2007) Xanthine oxidoreductase is a regulator of adipogenesis and PPARgamma activity. Cell Metab 5(2):115\u2013128. \nhttps:\/\/doi.org\/10.1016\/j.cmet.2007.01.005","journal-title":"Cell Metab"},{"issue":"5","key":"4737_CR25","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.semarthrit.2017.09.007","volume":"47","author":"L Scheepers","year":"2018","unstructured":"Scheepers L, van Onna M, Stehouwer CDA, Singh JA, Arts ICW, Boonen A (2018) Medication adherence among patients with gout: a systematic review and meta-analysis. Semin Arthritis Rheum 47(5):689\u2013702. \nhttps:\/\/doi.org\/10.1016\/j.semarthrit.2017.09.007","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"4737_CR26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s40744-016-0033-3","volume":"3","author":"R Morlock","year":"2016","unstructured":"Morlock R, Chevalier P, Horne L, Nuevo J, Storgard C, Aiyer L, Hines DM, Ansolabehere X, Nyberg F (2016) Disease control, health resource use, healthcare costs, and predictors in gout patients in the United States, the United Kingdom, Germany, and France: a retrospective analysis. Rheumatol Ther 3(1):53\u201375. \nhttps:\/\/doi.org\/10.1007\/s40744-016-0033-3","journal-title":"Rheumatol Ther"},{"issue":"4","key":"4737_CR27","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/tcm.1770070407","volume":"7","author":"K Winckler","year":"1987","unstructured":"Winckler K, Obe G, Madle S, Kocher-Becker U, Kocher W, Nau H (1987) Cyclophosphamide: interstrain differences in the production of mutagenic metabolites by S9-fractions from liver and kidney in different mutagenicity test systems in vitro and in the teratogenic response in vivo between CBA and C 57 BL mice. Teratog Carcinog Mutagen 7(4):399\u2013409","journal-title":"Teratog Carcinog Mutagen"},{"issue":"2","key":"4737_CR28","doi-asserted-by":"publisher","first-page":"R46","DOI":"10.1186\/ar2659","volume":"11","author":"LR Harrold","year":"2009","unstructured":"Harrold LR, Andrade SE, Briesacher BA, Raebel MA, Fouayzi H, Yood RA, Ockene IS (2009) Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther 11(2):R46. \nhttps:\/\/doi.org\/10.1186\/ar2659","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"4737_CR29","first-page":"1575","volume":"31","author":"AA Riedel","year":"2004","unstructured":"Riedel AA, Nelson M, Joseph-Ridge N, Wallace K, MacDonald P, Becker M (2004) Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol 31(8):1575\u20131581","journal-title":"J Rheumatol"},{"issue":"8","key":"4737_CR30","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1007\/s10067-018-4127-x","volume":"37","author":"CA Janssen","year":"2018","unstructured":"Janssen CA, Oude Voshaar MAH, Vonkeman HE, Krol M, van de Laar M (2018) A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in the Netherlands. Clin Rheumatol 37(8):2291\u20132296. \nhttps:\/\/doi.org\/10.1007\/s10067-018-4127-x","journal-title":"Clin Rheumatol"},{"issue":"3","key":"4737_CR31","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s10067-014-2823-8","volume":"35","author":"B McGowan","year":"2016","unstructured":"McGowan B, Bennett K, Silke C, Whelan B (2016) Adherence and persistence to urate-lowering therapies in the Irish setting. Clin Rheumatol 35(3):715\u2013721. \nhttps:\/\/doi.org\/10.1007\/s10067-014-2823-8","journal-title":"Clin Rheumatol"},{"issue":"23","key":"4737_CR32","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353(23):2450\u20132461. \nhttps:\/\/doi.org\/10.1056\/NEJMoa050373","journal-title":"N Engl J Med"},{"issue":"8","key":"4737_CR33","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/RHU.0000000000000322","volume":"21","author":"A Altan","year":"2015","unstructured":"Altan A, Shiozawa A, Bancroft T, Singh JA (2015) A real-world study of switching from allopurinol to febuxostat in a health plan database. J Clin Rheumatol 21(8):411\u2013418. \nhttps:\/\/doi.org\/10.1097\/RHU.0000000000000322","journal-title":"J Clin Rheumatol"},{"issue":"16","key":"4737_CR34","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.lfs.2004.10.031","volume":"76","author":"Y Takano","year":"2005","unstructured":"Takano Y, Hase-Aoki K, Horiuchi H, Zhao L, Kasahara Y, Kondo S, Becker MA (2005) Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase\/xanthine dehydrogenase. Life Sci 76(16):1835\u20131847. \nhttps:\/\/doi.org\/10.1016\/j.lfs.2004.10.031","journal-title":"Life Sci"},{"issue":"13","key":"4737_CR35","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","volume":"378","author":"WB White","year":"2018","unstructured":"White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, Hunt B, Castillo M, Gunawardhana L, Investigators C (2018) Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med 378(13):1200\u20131210. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1710895","journal-title":"N Engl J Med"},{"issue":"9","key":"4737_CR36","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s40265-016-0591-2","volume":"76","author":"G Derosa","year":"2016","unstructured":"Derosa G, Maffioli P, Reiner Z, Simental-Mendia LE, Sahebkar A (2016) Impact of statin therapy on plasma uric acid concentrations: a systematic review and meta-analysis. Drugs 76(9):947\u2013956. \nhttps:\/\/doi.org\/10.1007\/s40265-016-0591-2","journal-title":"Drugs"},{"issue":"4","key":"4737_CR37","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.ahj.2004.04.005","volume":"148","author":"HJ Milionis","year":"2004","unstructured":"Milionis HJ, Kakafika AI, Tsouli SG, Athyros VG, Bairaktari ET, Seferiadis KI, Elisaf MS (2004) Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart J 148(4):635\u2013640. \nhttps:\/\/doi.org\/10.1016\/j.ahj.2004.04.005","journal-title":"Am Heart J"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04737-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-019-04737-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04737-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T23:30:26Z","timestamp":1597188626000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-019-04737-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,13]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["4737"],"URL":"https:\/\/doi.org\/10.1007\/s10067-019-04737-5","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,13]]},"assertion":[{"value":"20 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"This clinical trial conformed to principles of the Declaration of Helsinki and the Good Clinical Practice of China and was approved by the Drug Clinical Trial Ethics Committee, Shandong Provincial Hospital. All participants provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}